Protocol Ledger

NCT07185373 · Phase II/III · RECRUITING

Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL

Interventional Phase II/III clinical trial protocol NCT07185373 sponsored by Huashan Hospital in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-10-01 Enrollment: 215 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07185373
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)215 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07185373
Protocol FieldVerified Registry Value
NCT IdentifierNCT07185373
Consolidated Lead SponsorHuashan Hospital
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment215 participants (ESTIMATED)
Registered Start Date2025-10-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07185373
Hospital Research SiteLocationSite Profile
Peking University Third HospitalBeijing, ChinaOpen Hospital Dossier ->
The First Affiliated Hospital of Nanchang UniversityNanchang, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI